The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
 
Zev A. Wainberg
No Relationships to Disclose
 
Geoffrey Shapiro
Consulting or Advisory Role - Chugai Pharma; G1 Therapeutics; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); Immune Design (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst)
 
Giuseppe Curigliano
No Relationships to Disclose
 
Stephen Leong
Research Funding - Pfizer
 
Rebecca Sophie Kristeleit
Honoraria - Clovis Oncology; Novartis; Roche/Genentech
Consulting or Advisory Role - Clovis Oncology; Novartis
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; PiQuR
 
Maria Alsina Maqueda
No Relationships to Disclose
 
Carolyn D. Britten
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); MEI Pharma (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Roche Pharma AG (Inst)
 
Michele Milella
No Relationships to Disclose
 
Mark R. Middleton
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Roche Pharma AG
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Roche Pharma AG (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck; Roche Pharma AG
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Merck; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Jose A. Lopez-Martin
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; Lilly; MSD; Roche Pharma AG
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche Pharma AG
 
Karen A. Gelmon
Consulting or Advisory Role - Pfizer
 
Nicoletta Brega
Employment - Pfizer
Leadership - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kristen J. Pierce
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Rachelle Perea
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Brett Edward Houk
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nuzhat Pathan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Patents, Royalties, Other Intellectual Property - Biogen
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Ashwin Gollerkeri
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Albiruni R. A. Razak
No Relationships to Disclose